Farmacologia y Toxicologia

  • ISSN: 2174-8365
  • Journal h-index: 1
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • OCLC- WorldCat
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page
Recommended Webinars & Conferences


Forsythia?s pharmacological evaluation and genetic toxicology

Max Planck* and Banjamen babrare

The primary component of Forsythia suspense, forsythin, is therapeutically used to treat fever, viral colds, gonorrhoea, and ulcers. The objective of this study was to assess the safety of forsythin for human use as well as any potential genetic harm. The Ames test, chromosomal aberration (CA) test, and bone marrow micronucleus (MN) test were used to evaluate the genetic toxicity of forsythin in vivo in accordance with GLP standards and test guidelines. In the Ames test, the number of His + revertant colonies was counted after five Salmonella typhimurium strains were subjected to varying forsythin concentrations in the presence or absence of the S9 mixture. In the CA test, chromosomal abnormalities were identified after treating Chinese hamster lung (CHL) fibroblast cells with various concentrations of forsythin, mitomycin C, or cyclophosphamide in the presence or absence of the S9 mixture. The MN test involved isolating the bone marrow from the mice that had received various treatments and calculating the ratios of polychromatic erythrocytes (PCE) and erythrocytes (PCE/(PCE + NCE)). Following the division of the beagle dogs into four groups-a negative control group, a lowdose group, a medium-dose group, and a high-dose group-a telemetry system was utilised to assess the safety of forsythin use. Results from the Ames test revealed that whether the S9 was present or not, there was no statistically dose-dependent increase in the number of colonies in any of the test strains.

When the S9 mixture was present, the number of cells with aberrations in the CHL fibroblast cells treated with low, medium, and high doses of forsythin for 24 or 48 hours was, respectively, 5.0/2.5, 4.5/1.5, and 5.0/5.0, and it was, respectively, 5.0, 5.0, and 4.5 when the S9 mixture was not present. These findings demonstrated that neither the presence (2.0) nor the absence (4.0/2.5 for 24/48 h) of the S9 combination significantly differed from the negative control group. The MN test revealed that forsythin had no cytotoxicity because the values of PCE/ (PCE + NCE) in the negative, positive controls, and forsythin treatment groups were all greater than 20%. Furthermore, the telemetry approach did not reveal any appreciable toxicological effects of forsythin on blood pressure, respiration, temperature, ECG, and other physiological indicators in the aware beagle dogs of different groups. Our results indicated that forsythin is suitable for continued development and prospective application because it has a negligible risk of genetic toxicity and no major toxicological consequences.

Published Date: 2022-09-05; Received Date: 2022-08-05